{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:33:15Z","timestamp":1762522395098,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01476","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T09:03:51Z","timestamp":1576573431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China"],"prefix":"10.3389","volume":"10","author":[{"given":"Xiaojian","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingpei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siliang","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"B2","first-page":"752","article-title":"Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis","volume":"28","author":"Aydin","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"B7","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","article-title":"Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study","volume":"42","author":"Heinonen","year":"2015","journal-title":"J. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3760\/cma.j.issn.0578-1426.2010.09.005","article-title":"A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis","volume":"49","author":"Huang","year":"2010","journal-title":"Zhonghua nei ke zazhi."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3760\/cma.j.issn.0578-1426.2011.12.013","article-title":"A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis","volume":"50","author":"Huang","year":"2011","journal-title":"Zhonghua nei ke za zhi."},{"key":"B12","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J. Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2171475","article-title":"Improvement of disease management and cost effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: a prospective cohort study","volume":"2019","author":"Ji","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","volume":"62","author":"Kristensen","year":"2010","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.5114\/aoms.2018.76141","article-title":"Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China","volume":"15","author":"Li","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/1467-9868.00183","article-title":"Inference in generalized additive mixed models by using smoothing splines","volume":"61","author":"Lin","year":"1999","journal-title":"J. R Stat. Soc. Ser. B Stat. Methodol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.38921","article-title":"Calculating the ankylosing spondylitis disease activity score if the conventional C-reactive protein level is below the limit of detection or if high-sensitivity C-reactive protein is used: an analysis in the DESIR cohort","volume":"67","author":"Machado","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B22","first-page":"958","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin. Exp. Rheumato."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3899\/jrheum.160594","article-title":"Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-\u03b1 inhibitors for up to 10 years","volume":"43","author":"Poddubnyy","year":"2016","journal-title":"J. Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kex475","article-title":"Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"57","author":"Poddubnyy","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/rheumatology\/ker270","article-title":"Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide","volume":"50","author":"van den Berg","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/rheumatology\/keu438","article-title":"Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab","volume":"54","author":"van der Heijde","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/annrheumdis-2012-202431","article-title":"Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies","volume":"72","author":"van der Horst-Bruinsma","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.semarthrit.2018.07.015","article-title":"Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable, male patients show more radiographic progression during treatment with TNF-alpha inhibitors","volume":"48","author":"van der Slik","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"B34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/1756-185X.12973","article-title":"Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis","volume":"21","author":"Wei","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000259","article-title":"Costs of drugs for treatment of rheumatic diseases","volume":"2","author":"Westhovens","year":"2016","journal-title":"RMD Open."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T09:03:57Z","timestamp":1576573437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":36,"alternative-id":["10.3389\/fphar.2019.01476"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01476","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"article-number":"1476"}}